Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Binglan Yu & Thomas Ming Swi Chang. (2002) IN VITRO ENZYME KINETICS OF MICROENCAPSULATED TYROSINASE. Artificial Cells, Blood Substitutes, and Biotechnology 30:5-6, pages 533-546.
Read now
Read now
Sarah Safos. (1995) Enzyme Replacement Therapy in ENU2 Phenylketonuric Mice Using Oral Microencapsulated Phenylalanine Ammonia-Lyase: A Preliminary Report. Artificial Cells, Blood Substitutes, and Biotechnology 23:6, pages 681-692.
Read now
Read now
Articles from other publishers (32)
Peng Gu, Li Xie, Tao Chen, Qin Yang, Xianglong Zhang, Ruofan Liu, Jiayin Guo, Rongjuan Wei, Dongping Li, Yong Jiang, Ye Chen, Wei Gong & Peng Chen. (2023) An engineered Escherichia coli Nissle strain prevents lethal liver injury in a mouse model of tyrosinemia type 1. Journal of Hepatology.
Crossref
Crossref
Kristen Skvorak, Joyce Liu, Nikki Kruse, Roasa Mehmood, Subhamoy Das, Stephan Jenne, Chinping Chng, U. Loi Lao, Da Duan, Jonathan Asfaha, Faye Du, Leann Teadt, Antionette Sero, Charlene Ching, James Riggins, Lianne Pope, Ping Yan, Harminder Mashiana, Moulay Hicham Alaoui Ismaili, Kerryn McCluskie, Gjalt Huisman & Adam P. Silverman. (2023)
Oral enzyme therapy for maple syrup urine disease (
MSUD
) suppresses plasma leucine levels in intermediate
MSUD
mice and healthy nonhuman primates
. Journal of Inherited Metabolic Disease 46:6, pages 1089-1103.
Crossref
Crossref
Jerry Vockley, Neal Sondheimer, Marja Puurunen, George A. Diaz, Ilona Ginevic, Dorothy K. Grange, Cary Harding, Hope Northrup, John A. PhillipsIIIIII, Shawn Searle, Janet A. Thomas, Roberto Zori, William S. Denney, Sharon L. Ernst, Kristina Humphreys, Nicole McWhorter, Caroline Kurtz & Aoife M. Brennan. (2023) Efficacy and safety of a synthetic biotic for treatment of phenylketonuria: a phase 2 clinical trial. Nature Metabolism 5:10, pages 1685-1690.
Crossref
Crossref
Kristen Skvorak, Vesna Mitchell, Leann Teadt, Kierra A. Franklin, Hyung-Ok Lee, Nikki Kruse, Callie Huitt-Roehl, Julie Hang, Faye Du, Stephanie Galanie, Steven Guan, Hera Aijaz, Nianliu Zhang, Gabriel Rajkovic, Warren D. Kruger, Moulay Hicham Alaoui Ismaili, Gjalt Huisman, Kerryn McCluskie & Adam P. Silverman. (2023) An orally administered enzyme therapeutic for homocystinuria that suppresses homocysteine by metabolizing methionine in the gastrointestinal tract. Molecular Genetics and Metabolism 139:4, pages 107653.
Crossref
Crossref
Luciana d’Amone, Vikas D. Trivedi, Nikhil U. Nair & Fiorenzo G. Omenetto. (2022) A Silk-Based Platform to Stabilize Phenylalanine Ammonia-lyase for Orally Administered Enzyme Replacement Therapy. Molecular Pharmaceutics 19:12, pages 4625-4630.
Crossref
Crossref
Matthew ChangKangsan Kim, Donghui Choe, Minjeong Kang, Bong Hyun Sung, Haseong Kim, Seung‐Goo Lee, Dae‐Hee Lee & Byung‐Kwan Cho. 2022. Principles in Microbiome Engineering. Principles in Microbiome Engineering
93
119
.
Aoife M Brennan. (2022) Development of synthetic biotics as treatment for human diseases. Synthetic Biology 7:1.
Crossref
Crossref
Els van der Goot, Stefanie N. Vink, Danique van Vliet, Francjan J. van Spronsen, Joana Falcao Salles & Eddy A. van der Zee. (2022) Gut-Microbiome Composition in Response to Phenylketonuria Depends on Dietary Phenylalanine in BTBR Pahenu2 Mice. Frontiers in Nutrition 8.
Crossref
Crossref
Zachary J. S. Mays & Nikhil U. Nair. (2021) A quantitative model for metabolic intervention using gut microbes. Biotechnology Progress 37:5.
Crossref
Crossref
Marja K. Puurunen, Jerry Vockley, Shawn L. Searle, Stephanie J. Sacharow, John A. PhillipsIIIIII, William S. Denney, Benjamin D. Goodlett, David A. Wagner, Larry Blankstein, Mary J. Castillo, Mark R. Charbonneau, Vincent M. Isabella, Vasu V. Sethuraman, Richard J. Riese, Caroline B. Kurtz & Aoife M. Brennan. (2021) Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study. Nature Metabolism 3:8, pages 1125-1132.
Crossref
Crossref
Mark R. Charbonneau, William S. Denney, Nicholas G. Horvath, Pasquale Cantarella, Mary J. Castillo, Marja K. Puurunen & Aoife M. Brennan. (2021) Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria. Communications Biology 4:1.
Crossref
Crossref
Francjan J. van Spronsen, Nenad Blau, Cary Harding, Alberto Burlina, Nicola Longo & Annet M. Bosch. (2021) Phenylketonuria. Nature Reviews Disease Primers 7:1.
Crossref
Crossref
M. Tyler Nelson, Mark R. Charbonneau, Heidi G. Coia, Mary J. Castillo, Corey Holt, Eric S. Greenwood, Peter J. Robinson, Elaine A. Merrill, David Lubkowicz & Camilla A. Mauzy. (2021) Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip. Nature Communications 12:1.
Crossref
Crossref
Irene Pereira de Sousa, Charlotte Gourmel, Olena Berkovska, Michael Burger & Jean-Christophe Leroux. (2020) A microparticulate based formulation to protect therapeutic enzymes from proteolytic digestion: phenylalanine ammonia lyase as case study. Scientific Reports 10:1.
Crossref
Crossref
Vincent M Isabella, Binh N Ha, Mary Joan Castillo, David J Lubkowicz, Sarah E Rowe, Yves A Millet, Cami L Anderson, Ning Li, Adam B Fisher, Kip A West, Philippa J Reeder, Munira M Momin, Christopher G Bergeron, Sarah E Guilmain, Paul F Miller, Caroline B Kurtz & Dean Falb. (2018) Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nature Biotechnology 36:9, pages 857-864.
Crossref
Crossref
Thomas Chang. 2015. Handbook of Encapsulation and Controlled Release. Handbook of Encapsulation and Controlled Release
907
915
.
Leticia Hosta-Rigau, Maria J. York-Duran, Tse Siang Kang & Brigitte Städler. (2015) Extracellular Microreactor for the Depletion of Phenylalanine Toward Phenylketonuria Treatment. Advanced Functional Materials 25:25, pages 3860-3869.
Crossref
Crossref
Arturo López-Villalobos, Joost Lücker, Ana Angela López-Quiróz, Edward C. Yeung, Kristoffer Palma & Allison R. Kermode. (2014) Preservation of high phenylalanine ammonia lyase activities in roots of Japanese Striped corn: A potential oral therapeutic to treat phenylketonuria. Cryobiology 68:3, pages 436-445.
Crossref
Crossref
Christineh N. Sarkissian, Tse Siang Kang, Alejandra Gámez, Charles R. Scriver & Raymond C. Stevens. (2011) Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria. Molecular Genetics and Metabolism 104:3, pages 249-254.
Crossref
Crossref
Woo-Mi Kim. (2009) Development of Modified Phenylalanine Ammonia-lyase for the Treatment of Phenylketonuria. Biomolecules and Therapeutics 17:1, pages 104-110.
Crossref
Crossref
Kiyoshi Takasuna, Chiba Katsuyoshi & Sunao Manabe. (2009) Pre-clinical QT Risk Assessment in Pharmaceutical Companies - Issues of Current QT Risk Assessment -. Biomolecules and Therapeutics 17:1, pages 1-11.
Crossref
Crossref
S PRAKASH, J R BHATHENA & H CHEN. 2007. Artificial Cells, Cell Engineering and Therapy. Artificial Cells, Cell Engineering and Therapy
3
41
.
Amaia Esquisabel, Rosa María Hernández, Alicia Rodríguez Gascón & José Luis Pedraz. 2006. Immobilization of Enzymes and Cells. Immobilization of Enzymes and Cells
283
293
.
Thomas Ming Swi Chang. (2005) Therapeutic applications of polymeric artificial cells. Nature Reviews Drug Discovery 4:3, pages 221-235.
Crossref
Crossref
Woomi Kim, Heidi Erlandsen, Sankar Surendran, Raymond C. Stevens, Stephen K. Tyring, Reuben Matalon, Alejandra Gamez & Kimberlee Michols-Matalon. (2004) Trends in Enzyme Therapy for Phenylketonuria. Molecular Therapy 10:2, pages 220-224.
Crossref
Crossref
Binglan Yu & Thomas Ming Swi Chang. (2004) Effects of long-term oral administration of polymeric microcapsules containing tyrosinase on maintaining decreased systemic tyrosine levels in rats. Journal of Pharmaceutical Sciences 93:4, pages 831-837.
Crossref
Crossref
J David McDonald, Maria Andriolo, Francesco Calı̀, Mario Mirisola, Stefano Puglisi-Allegra, Valentino Romano, Christineh N Sarkissian & Carolyn B Smith. (2002) The phenylketonuria mouse model: a meeting review. Molecular Genetics and Metabolism 76:4, pages 256-261.
Crossref
Crossref
Susan Habibi-Moini & Anil P D'mello. (2001) Evaluation of possible reasons for the low phenylalanine ammonia lyase activity in cellulose nitrate membrane microcapsules. International Journal of Pharmaceutics 215:1-2, pages 185-196.
Crossref
Crossref
Shigeo Kure, Dian-Chang Hou, Toshihiro Ohura, Hiroko Iwamoto, Shuhei Suzuki, Naruji Sugiyama, Osamu Sakamoto, Kunihiro Fujii, Yoichi Matsubara & Kuniaki Narisawa. (1999) Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. The Journal of Pediatrics 135:3, pages 375-378.
Crossref
Crossref
MATTHEUS F. A. GOOSEN. (2006) Physico‐chemical and Mass Transfer Considerations in Microencapsulation. Annals of the New York Academy of Sciences 875:1, pages 84-104.
Crossref
Crossref
Harvey L. Levy. (1999) Phenylketonuria: Old disease, new approach to treatment. Proceedings of the National Academy of Sciences 96:5, pages 1811-1813.
Crossref
Crossref
Osvaldo Freitas, Clarice Izumi, Marilisa G. Lara & Lewis J. Greene. (2009) New Approaches to the Treatment of Phenylketonuria. Nutrition Reviews 57:3, pages 65-70.
Crossref
Crossref